President Donald Trump announced in mid-August 2025 that his administration would decide within weeks whether to ease federal restrictions on cannabis. Whilst the marijuana industry has lobbied aggressively for this change, mounting evidence suggests such a policy shift would create severe consequences for public health and national security.

Understanding the Marijuana Rescheduling Risks

The Controlled Substances Act authorises federal authorities to classify drugs across five schedules based on abuse potential and medical utility. Cannabis currently occupies Schedule I, reserved for substances with no accepted medical use and high abuse risk.

In 2023, the Biden administration recommended relocating marijuana to Schedule III, a significantly less restrictive category. This change failed to materialise before Biden’s term concluded. The cannabis industry subsequently donated millions to Trump’s campaign, hoping the new administration would complete the rescheduling process.

However, the marijuana rescheduling risks associated with such policy changes extend far beyond industry profit margins. Public health data increasingly demonstrates the dangers of expanded cannabis access.

The Tax Code Windfall for Cannabis Companies

Federal law prohibits businesses from deducting most expenses related to selling Schedule I and Schedule II substances. This restriction currently applies to marijuana retailers, even in states where cannabis is legal.

Reclassifying marijuana as Schedule III would eliminate these constraints, allowing weed businesses to deduct operational expenses—including advertising costs—on tax returns. This represents a substantial financial windfall for the cannabis industry.

The implications for youth exposure are particularly concerning. When marijuana companies gain tax advantages for advertising spending, they inevitably increase marketing efforts. This expanded reach disproportionately affects young people, who are especially vulnerable to cannabis messaging on social media platforms.

Research from the University of Southern California confirms that teenagers exposed to marijuana content on social media demonstrate higher likelihood of drug use. This correlation underscores one of the key marijuana rescheduling risks: facilitating industry marketing that targets impressionable audiences.

Cannabis and Mental Health: The Evidence Mounts

The relationship between marijuana use and mental illness represents perhaps the most alarming aspect of marijuana rescheduling risks. Extensive research documents significant psychiatric dangers, particularly for young users.

A comprehensive literature review by Sorbonne researchers examined cannabis effects on adolescent mental health. The findings proved stark: among teenagers, marijuana use increases suicidal ideation risk by 46 percent and suicide attempt risk by 85 percent.

These statistics reflect genuine human tragedy. Families across Britain, America, and other nations have witnessed promising young lives derailed by cannabis-induced mental health crises.

The schizophrenia connection deserves particular attention. A longitudinal study from 2021 documented massive increases in marijuana-linked schizophrenia rates in Denmark. Researchers attributed this surge to the high potency of contemporary cannabis products, which contain THC concentrations far exceeding historical levels.

Young men face especially elevated risks. A 2023 study identified this demographic as particularly vulnerable to developing schizophrenia associated with cannabis-use disorder. This finding carries policy implications, particularly given that alienated young men represented a significant portion of Trump’s electoral coalition.

Cardiovascular Dangers: An Underreported Crisis

Beyond psychiatric effects, marijuana rescheduling risks encompass severe cardiovascular damage. Recent medical research has produced alarming data about cannabis effects on heart health.

A systematic review published in the British Medical Journal in June 2025 linked marijuana use to doubled risk of cardiovascular death. This finding emerged from rigorous analysis of multiple studies, establishing a clear statistical relationship between cannabis consumption and fatal heart events.

Further evidence appeared in a March meta-analysis published by the Journal of the American College of Cardiology. Examining approximately 75 million cases, researchers determined that marijuana users are 51 percent more likely than non-users to experience heart attacks.

These cardiovascular dangers affect users across age groups. The stereotype of cannabis as a relatively harmless substance cannot withstand scrutiny when confronted with such compelling medical evidence about cannabis rescheduling risks.

Illegal Markets and National Security Concerns

Rescheduling marijuana would paradoxically strengthen illegal drug markets, creating national security vulnerabilities. This represents an often-overlooked category of marijuana rescheduling risks that extends beyond individual health to community safety.

Chinese and Mexican cartels dominate America’s illegal drug trade. Any growth the legal cannabis industry experiences from rescheduling will ultimately benefit these international criminal organisations. The mechanisms are straightforward: expanded legal markets normalise cannabis use, increasing overall demand that illegal operators eagerly satisfy.

New York City illustrates this dynamic clearly. Despite New York State having legalised marijuana, approximately 3,600 illegal cannabis shops operate throughout the city. These unlicensed retailers undercut legal businesses whilst funnelling profits to organised crime networks.

For an administration emphasising border security and confronting Chinese influence, facilitating marijuana rescheduling would undermine stated policy objectives. The contradiction between tough rhetoric on cartels and policies that strengthen their financial position cannot be ignored.

The Addiction Industry Profits Whilst Communities Suffer

The cannabis industry frames rescheduling as a social equity issue or medical access question. This messaging obscures the commercial reality: the policy change primarily benefits corporate shareholders rather than communities.

Contemporary cannabis products bear little resemblance to the marijuana of previous decades. THC potency has increased dramatically, creating products more accurately described as concentrated drugs than plant material. These high-potency products drive the marijuana rescheduling risks documented in recent research.

The addiction industry, encompassing both legal marijuana businesses and illegal operators, profits from increased consumption. Meanwhile, families cope with the consequences: young people developing schizophrenia, adults experiencing heart attacks, and communities watching illegal markets flourish.

Policy Alternatives and Public Health Protection

Rejecting marijuana rescheduling need not mean ignoring legitimate medical research or maintaining ineffective enforcement approaches. Alternative policy frameworks exist that prioritise public health without creating the cannabis rescheduling risks associated with commercial markets.

Targeted medical access programmes can provide cannabis-derived medications to patients with specific conditions, using pharmaceutical standards for purity and dosage. This approach avoids the marijuana rescheduling risks created by commercial recreational markets whilst addressing genuine medical needs.

Enhanced enforcement against illegal markets, combined with prevention education highlighting cannabis dangers, offers a balanced strategy. Evidence-based prevention programmes can reach young people before they begin using marijuana, whilst enforcement efforts disrupt cartel operations.

The Decision Ahead

President Trump faces pressure from cannabis industry donors who expect returns on their campaign investments. However, the marijuana rescheduling risks documented by recent research present compelling reasons for maintaining current restrictions.

The evidence spans multiple domains: psychiatric effects including suicidal ideation and schizophrenia, cardiovascular dangers including doubled death risk, and national security concerns as illegal markets expand. These concerns affect the very constituencies Trump claims to champion, particularly young men vulnerable to cannabis-induced mental illness.

Policy decisions should reflect scientific evidence rather than industry lobbying. The accumulating research on marijuana rescheduling risks points towards maintaining federal restrictions that protect public health, even as commercial interests push for deregulation.

The coming weeks will reveal whether the administration prioritises campaign donors or the wellbeing of American families. For those tracking cannabis policy developments, the stakes extend far beyond tax policy to fundamental questions of public health protection and the marijuana rescheduling risks that threaten communities.

Source: City Journal